About DnaJ homolog subfamily B member 6
DnaJ homolog subfamily B member 6 (DNAJB6) is a protein
from Homo sapiens identified by UniProt accession
O75190, 326 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily B member 6 |
| UniProt accession | O75190 |
| Gene | DNAJB6 |
| Organism | Homo sapiens |
| Length | 326 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (109)
Diseases linked to this target (Open Targets).
- Autosomal dominant limb-girdle muscular dystrophy type 1D · score 0.78
- autosomal dominant limb-girdle muscular dystrophy type 1D (DNAJB6) · score 0.75
- Autosomal dominant limb-girdle muscular dystrophy · score 0.42
- muscular dystrophy, limb-girdle, autosomal dominant · score 0.37
- neurodegenerative disease · score 0.36
- Abnormality of the musculature · score 0.34
- Parkinson disease · score 0.26
- Hereditary late-onset Parkinson disease · score 0.26
- platelet crit · score 0.25
- genetic disorder · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75190-F1 | alphafold | PREDICTED | 62.96 | — |
Amino-acid sequence (326 residues)
MVDYYEVLGV QRHASPEDIK KAYRKLALKW HPDKNPENKE EAERKFKQVA EAYEVLSDAK KRDIYDKYGK EGLNGGGGGG SHFDSPFEFG FTFRNPDDVF REFFGGRDPF SFDFFEDPFE DFFGNRRGPR GSRSRGTGSF FSAFSGFPSF GSGFSSFDTG FTSFGSLGHG GLTSFSSTSF GGSGMGNFKS ISTSTKMVNG RKITTKRIVE NGQERVEVEE DGQLKSLTIN GVADDDALAE ERMRRGQNAL PAQPAGLRPP KPPRPASLLR HAPHCLSEEE GEQDRPRAPG PWDPLASAAG LKEGGKRKKQ KQREESKKKK STKGNH
Explore DnaJ homolog subfamily B member 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets